View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Theme
  2. Macro
  3. Covid-19
August 6, 2021

Coronavirus company news summary – Moderna vaccine shows durable efficacy up to six months – Regeneron antibody cocktail sales hit $2.59bn in Q2 2021

By Chris Lo

Final data from the Phase III COVE clinical trial of Moderna ’s Covid-19 vaccine has demonstrated 93% efficacy, durable up to six months after the second dose. The company added that its booster vaccine candidates also showed strong antibody responses against SARS-CoV-2 variants of concern in a Phase II trial.

Regeneron ‘s Covid-19 antibody cocktail, REGEN-COV, reached $2.59bn in net sales during the second quarter of 2021. Apart from the $34m net sales anticipated from the second supply agreement with the US government, Regeneron does not expect any more US sales of the product in the third quarter. The fourth quarter REGEN-COV sales in the country will depend on the number of Covid-19 cases and associated drug use, the company added.

Novavax and its partner Serum Institute of India (SII) have made submissions to regulatory agencies in India, Indonesia and the Philippines seeking emergency use authorisation for the former’s recombinant nanoparticle protein-based Covid-19 vaccine. The companies submitted data related to all modules, including preclinical, clinical, and chemistry, manufacturing and controls findings. SII has a vaccine manufacturing agreement to produce Novavax ’s jab, and is responsible for manufacturing and commercialising the vaccine in India.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology